Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer

NEXT STORY
BridgeBio Pharma, Inc. and Roswell Park Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Cancers
PREV STORY
BridgeBio Pharma, Inc. and GlycoNet Initiate Collaboration to Discover Potential Treatments for Genetic Diseases through Glycomics Research
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ELIGARD® (Leuprolide Acetate) for Injectable Suspension Continues Growth Momentum With Securing Favorable Formulary Position as the Lowest WAC Priced, and Only Subcutaneously Administered Leuprolide Acetate for the Palliative Treatment of Advanced Prostate Cancer

author_avatar
NASDAQ Market News

Stephen Ross, M.D., Chair of Reset Pharma’s Scientific Advisory Board to Deliver Keynote Presentation at The End in Mind Virtual Conference

author_avatar
NASDAQ Market News

Predictive Oncology Inc. Announces Newest Board Member

author_avatar
NASDAQ Market News